AI models applied to COVID-19–associated coagulopathy (CAC) consistently predicted thrombotic events and mortality, with D-dimer emerging as the most informative signal even inside multivariable, time-aware approaches. In a review of pandemic-era AI/ML studies in CAC, mechanistic analyses repeatedly converged on an IL-6–centered immunothrombotic network linking cytokine signaling with complement activation.

Why It Matters To Your Practice

• CAC is a thromboinflammatory syndrome with endothelial injury and micro-/macrovascular thrombosis; early risk identification can affect monitoring intensity, escalation decisions, and trial referral.

• D-dimer remains the most consistent lab abnormality and a practical severity marker—AI largely amplifies (rather than replaces) its prognostic value.

Clinical Implications

• Expect near-term AI tools to function as risk stratifiers built around routinely available labs (especially D-dimer), potentially enabling earlier identification of a high-risk minority.

• ML signals residual thrombotic risk despite standard thromboprophylaxis—supporting consideration of closer surveillance or enrollment into risk-adapted anticoagulation/immunomodulation trials when available.

• Be cautious when applying model outputs across sites: D-dimer assay heterogeneity and shifting variant/vaccination eras can degrade performance (model drift).

Insights

• Mechanistic ML repeatedly points to an IL-6–centered network tying inflammation to complement activation—suggesting actionable biology may be discoverable when proteomics and coagulation phenotyping are integrated.

• Time-aware models can capture dynamic risk (e.g., rising D-dimer trajectories), but most published CAC models remain retrospective with limited external validation.

The Bottom Line

• AI in COVID-19 CAC most reliably strengthens risk prediction anchored on D-dimer and helps map immunothrombotic mechanisms, but clinical adoption should wait for prospective validation and drift-resistant deployment.